Pomalidomide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Pomalidomide
   1. Pharmacist Assessment Report
   2. Pomalidomide: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Pomalidomide: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Pomalidomide, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	2
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
multiple myeloma	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
plasma cell myeloma

Australia Market Information

Licence	Product	Dosage form	Status
10386P	Pomalyst	Capsule 4 mg	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunomodulatory agent (thalidomide analogue); not a conventional cytotoxic
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI; haematological parameters (FBC with differential) are usually monitored for this drug class
Handling Protection	Please refer to the PI. Pomalidomide is a thalidomide analogue with known teratogenic risk, so precautions to avoid exposure in pregnancy are expected

Safety Considerations

Drug Interactions: The interaction screen returned 100 potential interactions in total, of which the first 20 were reviewed. Interactions rated Major include:

• Deferiprone
• Samarium (153Sm) lexidronam
• Human C1-esterase inhibitor
• Conestat alfa
• Darbepoetin alfa
• Erythropoietin
• Peginesatide

Interactions rated Moderate include clarithromycin, metronidazole, tinidazole, secnidazole, rosuvastatin, simvastatin, obeticholic acid, cobicistat, palifermin, strontium chloride Sr-89, fostamatinib, chloroquine and disulfiram.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---